

# Enriqueta Felip

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4221164/publications.pdf>

Version: 2024-02-01

232  
papers

52,511  
citations

10389

72  
h-index

1676

214  
g-index

239  
all docs

239  
docs citations

239  
times ranked

35629  
citing authors

#	ARTICLE	IF	CITATIONS
1	Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 1627-1639.	27.0	7,973
2	Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. <i>Lancet</i> , The, 2016, 387, 1540-1550.	13.7	5,456
3	Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2012, 13, 239-246.	10.7	4,943
4	Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2018, 378, 2078-2092.	27.0	4,701
5	First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2017, 376, 2415-2426.	27.0	2,145
6	AZD9291 in EGFR Inhibitor-Resistant Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2015, 372, 1689-1699.	27.0	1,802
7	Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2014, 370, 1189-1197.	27.0	1,367
8	Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. <i>Nature Medicine</i> , 2015, 21, 560-562.	30.7	1,280
9	Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. <i>New England Journal of Medicine</i> , 2020, 383, 1328-1339.	27.0	959
10	Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2518-2527.	1.6	811
11	First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 198-211.	10.7	773
12	Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and Tj ETQq0 0 QngBT /Overclock 10 T		
13	Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 2027-2039.	27.0	691
14	Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-III A non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. <i>Lancet</i> , The, 2021, 398, 1344-1357.	13.7	689
15	Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. <i>Nature Communications</i> , 2015, 6, 8839.	12.8	605
16	Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2018, 4, 351.	7.1	599
17	First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 2018-2029.	27.0	592
18	Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. <i>Lancet Oncology</i> , The, 2018, 19, 1654-1667.	10.7	587

#	ARTICLE	IF	CITATIONS
19	Lung Cancer That Harbors an <i>HER2</i> Mutation: Epidemiologic Characteristics and Therapeutic Perspectives. <i>Journal of Clinical Oncology</i> , 2013, 31, 1997-2003.	1.6	572
20	Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1590-1599.	10.7	535
21	COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. <i>Lancet Oncology</i> , The, 2020, 21, 914-922.	10.7	503
22	Tepotinib in Non-Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations. <i>New England Journal of Medicine</i> , 2020, 383, 931-943.	27.0	500
23	A Novel Anti-Apoptosis Gene: Re-expression of Survivin Messenger RNA as a Prognosis Marker in Non-Small-Cell Lung Cancers. <i>Journal of Clinical Oncology</i> , 1999, 17, 2100-2100.	1.6	475
24	Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. <i>Journal of Clinical Oncology</i> , 2017, 35, 1288-1296.	1.6	470
25	Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 874-886.	10.7	453
26	Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2016, 34, 3740-3748.	1.6	438
27	Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial. <i>Lancet Oncology</i> , The, 2016, 17, 452-463.	10.7	418
28	2nd ESMO Consensus Conference on Lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2014, 25, 1462-1474.	1.2	410
29	Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 897-907.	10.7	389
30	Preoperative Chemotherapy Plus Surgery Versus Surgery Plus Adjuvant Chemotherapy Versus Surgery Alone in Early-Stage Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 3138-3145.	1.6	351
31	Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). <i>Journal of Clinical Oncology</i> , 2017, 35, 2781-2789.	1.6	348
32	Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma. <i>Cancer Research</i> , 2017, 77, 3540-3550.	0.9	327
33	Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With <i>ALK</i> -Rearranged Non-Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2. <i>Journal of Clinical Oncology</i> , 2016, 34, 2866-2873.	1.6	316
34	2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. <i>Annals of Oncology</i> , 2015, 26, 1573-1588.	1.2	308
35	Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in <i>ALK</i> -Mutation-Positive Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 2251-2258.	1.6	308
36	<i>ALK</i> Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 1370-1379.	1.6	282

#	ARTICLE	IF	CITATIONS
37	Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With <i>EGFR</i> -Mutated, MET Factor-Overexpressing Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2018, 36, 3101-3109.	1.6	252
38	Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. <i>Annals of Oncology</i> , 2014, 25, 1681-1690.	1.2	246
39	Association of <i>EGFR</i> L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial. <i>JAMA Oncology</i> , 2015, 1, 149.	7.1	224
40	Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 3592-3603.	1.6	224
41	Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced <i>ALK</i> -Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014. <i>Journal of Clinical Oncology</i> , 2016, 34, 2858-2865.	1.6	216
42	The Impact of <i>EGFR</i> T790M Mutations and <i>BIM</i> mRNA Expression on Outcome in Patients with <i>EGFR</i> -Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial. <i>Clinical Cancer Research</i> , 2014, 20, 2001-2010.	7.0	215
43	2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. <i>Annals of Oncology</i> , 2014, 25, 1475-1484.	1.2	210
44	Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studies. <i>Lung Cancer</i> , 2019, 135, 188-195.	2.0	189
45	The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2017, 12, 194-207.	1.1	186
46	Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM). <i>PLoS ONE</i> , 2015, 10, e0121071.	2.5	185
47	Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. <i>Lancet Respiratory Medicine</i> , 2017, 5, 435-444.	10.7	172
48	Serum Tumor Markers CEA, CYFRA21-1, and CA-125 Are Associated With Worse Prognosis In Advanced Non-Small-Cell Lung Cancer (NSCLC). <i>Clinical Lung Cancer</i> , 2011, 12, 172-179.	2.6	171
49	Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With <i>EGFR</i> Exon 20 Insertion-Positive Metastatic Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2021, 7, e214761.	7.1	160
50	TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial. <i>Lancet Oncology</i> , 2016, 17, 212-223.	10.7	158
51	Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial. <i>Journal of Thoracic Oncology</i> , 2021, 16, 2091-2108.	1.1	156
52	Clinical Portrait of the SARS-CoV-2 Epidemic in European Patients with Cancer. <i>Cancer Discovery</i> , 2020, 10, 1465-1474.	9.4	151
53	Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1319-1327.	1.1	138
54	Pembrolizumab in patients with advanced non-small-cell lung cancer (KEYNOTE-001): 3-year results from an open-label, phase 1 study. <i>Lancet Respiratory Medicine</i> , 2019, 7, 347-357.	10.7	137

#	ARTICLE	IF	CITATIONS
55	Phase II Proof-of-Concept Study of Pazopanib Monotherapy in Treatment-Naive Patients With Stage I/II Resectable Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 3131-3137.	1.6	136
56	Single-cell transcriptome conservation in cryopreserved cells and tissues. <i>Genome Biology</i> , 2017, 18, 45.	8.8	134
57	Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1818-1831.	1.1	133
58	Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial. <i>Annals of Oncology</i> , 2016, 27, 417-423.	1.2	122
59	Osimertinib Western and Asian clinical pharmacokinetics in patients and healthy volunteers: implications for formulation, dose, and dosing frequency in pivotal clinical studies. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 77, 767-776.	2.3	118
60	Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer. <i>Nature Communications</i> , 2017, 8, 410.	12.8	117
61	Overcoming EGFRG724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors. <i>Nature Communications</i> , 2018, 9, 4655.	12.8	107
62	Clinical Management of Adverse Events Associated with Lorlatinib. <i>Oncologist</i> , 2019, 24, 1103-1110.	3.7	101
63	Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP). <i>Journal of Thoracic Oncology</i> , 2019, 14, 1086-1094.	1.1	99
64	ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer. <i>ESMO Open</i> , 2020, 5, e000820.	4.5	96
65	Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01. <i>Journal of Clinical Oncology</i> , 2020, 38, 9504-9504.	1.6	91
66	Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer. <i>Targeted Oncology</i> , 2020, 15, 55-65.	3.6	86
67	Updated Overall Survival Analysis From IMpower110: Atezolizumab Versus Platinum-Based Chemotherapy in Treatment-Naive Programmed Death-Ligand 1 Selected NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1872-1882.	1.1	85
68	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. <i>ESMO Open</i> , 2016, 1, e000097.	4.5	82
69	Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 341-352.	4.2	82
70	Progression-Free and Overall Survival for Concurrent Nivolumab With Standard Concurrent Chemoradiotherapy in Locally Advanced Stage IIIA-B NSCLC: Results From the European Thoracic Oncology Platform NICOLAS Phase II Trial (European Thoracic Oncology Platform 6-14). <i>Journal of Thoracic Oncology</i> , 2021, 16, 278-288.	1.1	82
71	Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients (pts) with EGFR inhibitor-resistant non-small cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , 2014, 32, 8009-8009.	1.6	81
72	Safety and Efficacy of Crizotinib in Patients With Advanced or Metastatic ROS1-Rearranged Lung Cancer (EUCROSS): A European Phase II Clinical Trial. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1266-1276.	1.1	78

#	ARTICLE	IF	CITATIONS
73	Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2015, 33, LBA109-LBA109.	1.6	74
74	A Phase II Pharmacodynamic Study of Erlotinib in Patients with Advanced Non-“Small Cell Lung Cancer Previously Treated with Platinum-Based Chemotherapy. Clinical Cancer Research, 2008, 14, 3867-3874.	7.0	73
75	Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study. Lancet Oncology, The, 2021, 22, 1669-1680.	10.7	73
76	Safety and Efficacy of First-Line Bevacizumab Plus Chemotherapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer: Safety of Avastin in Lung trial (MO19390). Journal of Thoracic Oncology, 2012, 7, 203-211.	1.1	70
77	Fluorescence In Situ Hybridization and Immunohistochemistry as Diagnostic Methods for ALK Positive Non-Small Cell Lung Cancer Patients. PLoS ONE, 2013, 8, e52261.	2.5	68
78	Drug development to overcome resistance to EGFR inhibitors in lung and colorectal cancer. Molecular Oncology, 2012, 6, 15-26.	4.6	66
79	Genomic Profiling of Patient-Derived Xenografts for Lung Cancer Identifies <i>B2M</i> Inactivation Impairing Immunorecognition. Clinical Cancer Research, 2017, 23, 3203-3213.	7.0	66
80	Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscape Project. Journal of Thoracic Oncology, 2018, 13, 413-425.	1.1	66
81	Treatment of Elderly Patients With Non-“Small-Cell Lung Cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. Clinical Lung Cancer, 2015, 16, 325-333.	2.6	65
82	Phase 2 Study of the HSP-90 Inhibitor AUY922 in Previously Treated and Molecularly Defined Patients with Advanced Non-“Small Cell Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 576-584.	1.1	62
83	Association of <i>ERBB</i> Mutations With Clinical Outcomes of Afatinib- or Erlotinib-Treated Patients With Lung Squamous Cell Carcinoma. JAMA Oncology, 2018, 4, 1189.	7.1	53
84	Personalizing Therapy with Targeted Agents in Non-Small Cell Lung Cancer. Oncotarget, 2011, 2, 165-177.	1.8	52
85	The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skipping. Cancer Treatment Reviews, 2020, 87, 102022.	7.7	51
86	YES1 Drives Lung Cancer Growth and Progression and Predicts Sensitivity to Dasatinib. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 888-899.	5.6	50
87	Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-“Expressing NSCLC. Journal of Thoracic Oncology, 2019, 14, 793-801.	1.1	50
88	Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer. European Journal of Cancer, 2019, 108, 120-128.	2.8	50
89	Time-Dependent COVID-19 Mortality in Patients With Cancer. JAMA Oncology, 2022, 8, 114.	7.1	50
90	Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study. Lancet Oncology, The, 2022, 23, 865-875.	10.7	50

#	ARTICLE	IF	CITATIONS
91	Assessment of a New ROS1 Immunohistochemistry Clone (SP384) for the Identification of ROS1 Rearrangements in Patients with Non-Small Cell Lung Carcinoma: the ROSING Study. <i>Journal of Thoracic Oncology</i> , 2019, 14, 2120-2132.	1.1	48
92	Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study. <i>Lancet Respiratory Medicine</i> , 2020, 8, 561-572.	10.7	47
93	Avelumab (anti-PD-L1) in combination with crizotinib or lorlatinib in patients with previously treated advanced NSCLC: Phase 1b results from JAVELIN Lung 101. <i>Journal of Clinical Oncology</i> , 2018, 36, 9008-9008.	1.6	47
94	Genomic Analyses across Six Cancer Types Identify Basal-like Breast Cancer as a Unique Molecular Entity. <i>Scientific Reports</i> , 2013, 3, 3544.	3.3	45
95	Phase I Safety and Pharmacokinetic Study of the PI3K/mTOR Inhibitor SAR245409 (XL765) in Combination with Erlotinib in Patients with Advanced Solid Tumors. <i>Journal of Thoracic Oncology</i> , 2014, 9, 316-323.	1.1	44
96	First-line crizotinib versus pemetrexed + cisplatin or pemetrexed + carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014). <i>Journal of Clinical Oncology</i> , 2014, 32, 8002-8002.	1.6	44
97	Clinical Response to a Lapatinib-Based Therapy for a Li-Fraumeni Syndrome Patient with a Novel <i>HER2</i> V659E Mutation. <i>Cancer Discovery</i> , 2013, 3, 1238-1244.	9.4	43
98	HER2 driven non-small cell lung cancer (NSCLC): potential therapeutic approaches. <i>Translational Lung Cancer Research</i> , 2013, 2, 122-7.	2.8	43
99	Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: A phase I dose-escalation study. <i>Lung Cancer</i> , 2010, 70, 180-187.	2.0	41
100	Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study. <i>European Journal of Cancer</i> , 2018, 101, 201-209.	2.8	41
101	Tissue sampling in lung cancer: A review in light of the MERIT experience. <i>Lung Cancer</i> , 2011, 74, 1-6.	2.0	40
102	Management of crizotinib therapy for ALK-rearranged non-small cell lung carcinoma: An expert consensus. <i>Lung Cancer</i> , 2015, 87, 89-95.	2.0	40
103	Role of ctDNA in Breast Cancer. <i>Cancers</i> , 2022, 14, 310.	3.7	40
104	Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with Bac2/BCG in responding patients with limited disease small-cell lung cancer. <i>European Journal of Cancer</i> , 2008, 44, 2178-2184.	2.8	39
105	Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2019, 24, 1095-1102.	3.7	37
106	Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study. <i>European Journal of Cancer</i> , 2021, 150, 190-202.	2.8	37
107	Guidelines for biomarker testing in advanced non-small-cell lung cancer. A national consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP). <i>Clinical and Translational Oncology</i> , 2012, 14, 338-349.	2.4	35
108	An Open-Label, Multicenter, Randomized, Phase II Study of Pazopanib in Combination with Pemetrexed in First-Line Treatment of Patients with Advanced-Stage Non-Small-Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1529-1537.	1.1	33

#	ARTICLE	IF	CITATIONS
109	Adjuvant Therapy in Non-Small Cell Lung Cancer: Future Treatment Prospects and Paradigms. <i>Clinical Lung Cancer</i> , 2011, 12, 261-271.	2.6	32
110	Lungscape: Resected Non-Small-Cell Lung Cancer Outcome by Clinical and Pathological Parameters. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1675-1684.	1.1	31
111	Safety and efficacy of INC280 in combination with gefitinib (gef) in patients with EGFR-mutated (mut), MET-positive NSCLC: A single-arm phase Ib/II study. <i>Journal of Clinical Oncology</i> , 2014, 32, 8017-8017.	1.6	31
112	Acute interstitial nephritis associated with immune checkpoint inhibitors: a single-centre experience. <i>CKJ: Clinical Kidney Journal</i> , 2021, 14, 1364-1370.	2.9	30
113	Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score. <i>Journal of Clinical Oncology</i> , 2021, 9, e002277.		30
114	Strategies for improving outcomes in NSCLC: A look to the future. <i>Lung Cancer</i> , 2013, 82, 375-382.	2.0	29
115	Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: a phase I/II randomized trial. <i>Experimental Hematology and Oncology</i> , 2014, 3, 26.	5.0	29
116	Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity. <i>Clinical Cancer Research</i> , 2017, 23, 5406-5415.	7.0	29
117	Cyclin-dependent Kinases as Emerging Targets for Developing Novel Antiviral Therapeutics. <i>Trends in Microbiology</i> , 2021, 29, 836-848.	7.7	29
118	First-in-human phase I study of the ALK inhibitor LDK378 in advanced solid tumors. <i>Journal of Clinical Oncology</i> , 2012, 30, 3007-3007.	1.6	29
119	Necitumumab in the treatment of advanced non-small cell lung cancer: translation from preclinical to clinical development. <i>Expert Opinion on Biological Therapy</i> , 2011, 11, 1223-1231.	3.1	28
120	Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy. <i>Clinical Lung Cancer</i> , 2018, 19, 74-83.e11.	2.6	28
121	Phase II study of the HSP90 inhibitor AUY922 in patients with previously treated, advanced non-small cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , 2012, 30, 7543-7543.	1.6	28
122	Clinical activity and safety of PF-06463922 from a dose escalation study in patients with advanced ALK+ or ROS1+ NSCLC. <i>Journal of Clinical Oncology</i> , 2015, 33, 8018-8018.	1.6	27
123	Evaluation of the VeriStrat Â® serum protein test in patients with advanced squamous cell carcinoma of the lung treated with second-line afatinib or erlotinib in the phase III LUX-Lung 8 study. <i>Lung Cancer</i> , 2017, 109, 101-108.	2.0	25
124	Testing for excision repair cross-complementing 1 in patients with non-small-cell lung cancer for chemotherapy response. <i>Expert Review of Molecular Diagnostics</i> , 2007, 7, 261-268.	3.1	24
125	Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. <i>Radiotherapy and Oncology</i> , 2019, 133, 163-166.	0.6	24
126	Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance. <i>Lung Cancer</i> , 2019, 134, 72-78.	2.0	24



#	ARTICLE	IF	CITATIONS
127	Ceritinib in advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) non-small cell lung cancer (NSCLC): Results of the ASCEND-1 trial.. Journal of Clinical Oncology, 2014, 32, 8003-8003.	1.6	24
128	Thoracic Oncology HERMES syllabus: setting the basis for thoracic oncology training in Europe: Table 1â€“. European Respiratory Journal, 2013, 42, 568-571.	6.7	23
129	A randomized phase 2 trial of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with erlotinib in EGFR wild-type NSCLC patients.. Journal of Clinical Oncology, 2014, 32, 8051-8051.	1.6	22
130	Economic Analysis of First-Line Treatment with Erlotinib in an EGFR -Mutated Population with Advanced NSCLC. Journal of Thoracic Oncology, 2016, 11, 801-807.	1.1	21
131	Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-Î² and PD-L1, in Patients with Esophageal Adenocarcinoma: Results from a Phase 1 Cohort. Targeted Oncology, 2021, 16, 435-446.	3.6	21
132	A Phase Ib, Dose-Finding Study of Erlotinib in Combination With a Fixed Dose of Pertuzumab in Patients With Advanced Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2012, 13, 432-441.	2.6	19
133	Molecular targeted therapy for early-stage non-small-cell lung cancer: Will it increase the cure rate?. Lung Cancer, 2014, 84, 97-100.	2.0	19
134	Phase Iâ€“IIa study of BMS-690514, an EGFR, HER-2 and -4 and VEGFR-1 to -3 oral tyrosine kinase inhibitor, in patients with advanced or metastatic solid tumours. European Journal of Cancer, 2013, 49, 1815-1824.	2.8	18
135	Thoracic oncology HERMES: European curriculum recommendations for training in thoracic oncology. Breathe, 2016, 12, 249-255.	1.3	18
136	First-in-human phase I study of EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor, in advanced non-small cell lung cancer (NSCLC) harboring T790M.. Journal of Clinical Oncology, 2015, 33, 8013-8013.	1.6	18
137	Clinical experience with erlotinib in non-small-cell lung cancer (NSCLC). Drugs of Today, 2006, 42, 147.	1.1	17
138	Real-world data on T-DM1 efficacy â€“ results of a single-center retrospective study of HER2-positive breast cancer patients. Scientific Reports, 2019, 9, 12760.	3.3	17
139	Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung Cancer. JCO Precision Oncology, 2019, 3, 1-14.	3.0	17
140	Evolution and Clinical Impact of EGFR Mutations in Circulating Free DNA in the BELIEF Trial. Journal of Thoracic Oncology, 2020, 15, 416-425.	1.1	17
141	Olmotinib in T790Mâ€“positive nonâ€“small cell lung cancer after failure of firstâ€“line epidermal growth factor receptorâ€“tyrosine kinase inhibitor therapy: A global, phase 2 study. Cancer, 2021, 127, 1407-1416.	4.1	17
142	EGFR compound mutants and survival on erlotinib in non-small cell lung cancer (NSCLC) patients (p) in the EURTAC study.. Journal of Clinical Oncology, 2012, 30, 7522-7522.	1.6	17
143	Clinical surrogate markers of survival in advanced non-small cell lung cancer (NSCLC) patients treated with secondâ€“third line erlotinib. Lung Cancer, 2009, 66, 257-261.	2.0	16
144	Activity of HSP90 Inhibitor in a Metastatic Lung Cancer Patient With a Germline BRCA1 Mutation. Journal of the National Cancer Institute, 2018, 110, 914-917.	6.3	16

#	ARTICLE	IF	CITATIONS
145	A phase II study of bemcentinib (BGB324), a first-in-class highly selective AXL inhibitor, with pembrolizumab in pts with advanced NSCLC: OS for stage I and preliminary stage II efficacy.. Journal of Clinical Oncology, 2019, 37, 9098-9098.	1.6	16
146	SEOM guidelines for the management of non-small-cell lung cancer (NSCLC). Clinical and Translational Oncology, 2009, 11, 284-289.	2.4	14
147	Adjuvant treatment of resected nonsmall cell lung cancer. Current Opinion in Oncology, 2013, 25, 115-120.	2.4	14
148	An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer. Lung Cancer, 2019, 136, 74-79.	2.0	14
149	Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts. Radiotherapy and Oncology, 2019, 135, 74-77.	0.6	14
150	Pharmacological Modulation of SAMHD1 Activity by CDK4/6 Inhibitors Improves Anticancer Therapy. Cancers, 2020, 12, 713.	3.7	14
151	COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry. Journal of the National Cancer Institute, 2022, 114, 979-987.	6.3	14
152	The Evolving Role of Nivolumab in Non-“Small-Cell Lung Cancer for Second-Line Treatment: A New Cornerstone for Our Treatment Algorithms. Results From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology. Clinical Lung Cancer, 2016, 17, 161-168.	2.6	13
153	A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer. ESMO Open, 2019, 4, e000532.	4.5	13
154	Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2015, 33, LBA109-LBA109.	1.6	13
155	Pemetrexed as second-line therapy for advanced non-small-cell lung cancer (NSCLC). Therapeutics and Clinical Risk Management, 2008, Volume 4, 579-585.	2.0	12
156	The accelerated path of ceritinib: Translating pre-clinical development into clinical efficacy. Cancer Treatment Reviews, 2017, 55, 181-189.	7.7	12
157	Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol. Clinical Lung Cancer, 2019, 20, e407-e412.	2.6	12
158	New therapeutic approaches to overcoming resistant EGFR exon 20 alterations. Critical Reviews in Oncology/Hematology, 2020, 151, 102990.	4.4	12
159	Optimizing PD-L1 as a biomarker of response with pembrolizumab (pembro; MK-3475) as first-line therapy for PD-L1-“positive metastatic non-small cell lung cancer (NSCLC): Updated data from KEYNOTE-001.. Journal of Clinical Oncology, 2015, 33, 8026-8026.	1.6	12
160	A randomized, double-blind, phase III study comparing two doses of erlotinib for second-line treatment of current smokers with advanced non-small-cell lung cancer (CurrentS). Lung Cancer, 2016, 99, 94-101.	2.0	11
161	LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology. Cancer Medicine, 2021, 10, 5878-5888.	2.8	11
162	Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer. Cancers, 2022, 14, 3305.	3.7	11

#	ARTICLE	IF	CITATIONS
163	Immunotherapy of non-small cell lung cancer: report from an international experts panel meeting of the Italian association of thoracic oncology. Expert Opinion on Biological Therapy, 2016, 16, 1479-1489.	3.1	10
164	Evolving Landscape of Molecular Prescreening Strategies for Oncology Early Clinical Trials. JCO Precision Oncology, 2020, 4, 505-513.	3.0	10
165	Concordance of PD-L1 expression by different immunohistochemistry (IHC) definitions and in situ hybridization (ISH) in squamous cell carcinoma (SCC) of the lung.. Journal of Clinical Oncology, 2014, 32, 7569-7569.	1.6	10
166	Neoadjuvant chemotherapy in early-stage non-small cell lung cancer. Translational Lung Cancer Research, 2013, 2, 398-402.	2.8	10
167	Recomendaciones para la determinaci3n de biomarcadores en el carcinoma de pulm3n no microc3tico avanzado. Consenso nacional de la Sociedad Espaola de Anatom3a Patol3gica y de la Sociedad Espaola de Oncolog3a M3dica. Revista Espanola De Patologia, 2012, 45, 14-28.	0.2	9
168	Lung Cancer in Never-Smoking Women: A Sub-Analysis of the Spanish Female-Specific Database WORLD07. Cancer Investigation, 2017, 35, 358-365.	1.3	9
169	Pembrolizumab in advanced pretreated small cell lung cancer patients with PD-L1 expression: data from the KEYNOTE-028 trial: a reason for hope?. Translational Lung Cancer Research, 2017, 6, S78-S83.	2.8	9
170	5 protein-based signature for resectable lung squamous cell carcinoma improves the prognostic performance of the TNM staging. Thorax, 2019, 74, 371-379.	5.6	9
171	A multicenter, phase II study of soluble LAG-3 (Eftilagimod alpha) in combination with pembrolizumab (TACTI-002) in patients with advanced non-small cell lung cancer (NSCLC) or head and neck squamous cell carcinoma (HNSCC).. Journal of Clinical Oncology, 2019, 37, TPS2667-TPS2667.	1.6	9
172	Lung Cancer in Women with a Family History of Cancer: The Spanish Female-specific Database WORLD07. Anticancer Research, 2016, 36, 6647-6654.	1.1	9
173	A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry. Journal of Thoracic Oncology, 2022, 17, 661-674.	1.1	9
174	Encorafenib plus binimetinib in patients with <i>BRAF</i> <sup>V600</sup> -mutant non-small cell lung cancer: phase II PHAROS study design. Future Oncology, 2022, 18, 781-791.	2.4	9
175	Dual effect of the broad spectrum kinase inhibitor midostaurin in acute and latent HIV-1 infection. Antiviral Research, 2019, 168, 18-27.	4.1	8
176	Afatinib (A) vs erlotinib (E) as second-line therapy of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following platinum-based chemotherapy: Overall survival (OS) analysis from the global phase III trial LUX-Lung 8 (LL8).. Journal of Clinical Oncology, 2015, 33, 8002-8002.	1.6	8
177	Monitoring <i>EGFR</i> -T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer. Oncotarget, 2018, 9, 27074-27086.	1.8	8
178	PI3K Pathway in NSCLC. Frontiers in Oncology, 2012, 1, 55.	2.8	7
179	Second-Line Treatment Options in Non-Small-Cell Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology. Clinical Lung Cancer, 2018, 19, 301-314.	2.6	7
180	Real-world treatment outcomes with brigatinib in patients with pretreated ALK+ metastatic non-small cell lung cancer. Lung Cancer, 2021, 157, 9-16.	2.0	7

#	ARTICLE	IF	CITATIONS
181	Ceritinib in Asian versus Caucasian patients (Pts) with advanced anaplastic lymphoma kinase (ALK)-rearranged (ALK+) NSCLC: Subgroup analysis of the ASCEND-1 trial.. Journal of Clinical Oncology, 2014, 32, 8078-8078.	1.6	7
182	Modulation of DNA Damage Response by SAM and HD Domain Containing Deoxynucleoside Triphosphate Triphosphohydrolase (SAMHD1) Determines Prognosis and Treatment Efficacy in Different Solid Tumor Types. Cancers, 2022, 14, 641.	3.7	7
183	First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers. Cancer Chemotherapy and Pharmacology, 2022, 89, 499-514.	2.3	7
184	Lung cancer in Spanish women: The WORLD07 project. European Journal of Cancer Care, 2019, 28, e12941.	1.5	6
185	Galaxy-2 trial (NCT01798485): A randomized phase 3 study of ganetespib in combination with docetaxel versus docetaxel alone in patients with advanced lung adenocarcinoma.. Journal of Clinical Oncology, 2014, 32, TPS8118-TPS8118.	1.6	6
186	Randomized open-label study of M7824 versus pembrolizumab as first-line (1L) treatment in patients with PD-L1 expressing advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2019, 37, TPS9114-TPS9114.	1.6	6
187	Clinical Significance of Hypoxia-Inducible Factor-1 $\alpha$ Messenger RNA Expression in Locally Advanced Non-Small-Cell Lung Cancer After Platinum Agent and Gemcitabine Chemotherapy Followed by Surgery. Clinical Lung Cancer, 2005, 6, 299-303.	2.6	5
188	HIV-Positive Patients with Lung Cancer: Is Immunotherapy a Safe and Active Option for Them?. Journal of Thoracic Oncology, 2018, 13, 874-876.	1.1	5
189	Phase I/II study of PF-06463922, an ALK/ROS1 tyrosine kinase inhibitor, in patients with advanced non-small-cell lung cancer harboring specific molecular alterations.. Journal of Clinical Oncology, 2015, 33, TPS2620-TPS2620.	1.6	5
190	Phase II open-label, multi-centre study of bemcentinib (BGB324), a first-in-class selective AXL inhibitor, in combination with pembrolizumab in patients with advanced NSCLC.. Journal of Clinical Oncology, 2018, 36, 3078-3078.	1.6	5
191	COVID-19 in breast cancer patients: a subanalysis of the OnCovid registry. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110534.	3.2	5
192	COX-2 inhibitors in NSCLC: never-ending story or misplaced?. Translational Lung Cancer Research, 2018, 7, S191-S194.	2.8	4
193	Specialist palliative and end-of-life care for patients with cancer and SARS-CoV-2 infection: a European perspective. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110422.	3.2	4
194	Genetic evolution to tyrosine kinase inhibitory therapy in patients with EGFR-mutated non-small-cell lung cancer. British Journal of Cancer, 2021, 125, 1561-1569.	6.4	4
195	Women in Oncology: Progress, Challenges, and Keys to Success. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2013, 33, 448-455.	3.8	4
196	Phase IB study to evaluate efficacy and tolerability of olaparib (AZD2281) plus gefitinib in patients (P) with epidermal growth factor receptor (EGFR) mutation positive advanced non-small cell lung cancer (NSCLC) (NCT=1513174/GECP-GOAL).. Journal of Clinical Oncology, 2014, 32, 8079-8079.	1.6	4
197	Computed tomography (CT) predicts accurately the pathologic tumour size in stage I non-small-cell lung cancer (NSCLC). Clinical and Translational Oncology, 2010, 12, 829-835.	2.4	3
198	A phase I, open-label, dose-escalation trial of BI 764532, a DLL3/CD3 bispecific antibody, in patients (pts) with small cell lung carcinoma (SCLC) or other neuroendocrine neoplasms expressing DLL3.. Journal of Clinical Oncology, 2021, 39, TPS8588-TPS8588.	1.6	3

#	ARTICLE	IF	CITATIONS
199	Menstrual status and lung cancer in female patients from the Spanish WORLD07 database.. Journal of Clinical Oncology, 2012, 30, e12012-e12012.	1.6	3
200	Phase IB study of olaparib (AZD2281) plus gefitinib in EGFR-mutant patients (p) with advanced non-small-cell lung cancer (NSCLC) (NCT01513174/GECP-GOAL).. Journal of Clinical Oncology, 2013, 31, 2581-2581.	1.6	3
201	Multiarm, nonrandomized, open-label phase IB study to evaluate FP1039/GSK3052230 with chemotherapy in NSCLC and MPM with deregulated FGF pathway signaling.. Journal of Clinical Oncology, 2014, 32, TPS8120-TPS8120.	1.6	3
202	Results of the phase IIb part of TIME study evaluating TG4010 immunotherapy in stage IV non-small cell lung cancer (NSCLC) patients receiving first line chemotherapy.. Journal of Clinical Oncology, 2015, 33, 3034-3034.	1.6	3
203	Bone metastases with nerve root compression as a late complication in patient with epithelial pleural mesothelioma. Journal of Thoracic Disease, 2013, 5, E35-7.	1.4	3
204	Targeted Therapies Development in the Treatment of Advanced Nonsmall Cell Lung Cancer. Journal of Biomedicine and Biotechnology, 2011, 2011, 1-2.	3.0	2
205	Ganitumab for the treatment of small-cell lung cancer. Expert Opinion on Investigational Drugs, 2014, 23, 1423-1432.	4.1	2
206	Skin toxicity associated with outcome to erlotinib in non-small cell lung cancer (NSCLC) patients (p) with EGFR mutations in the EURTAC study.. Journal of Clinical Oncology, 2012, 30, 7542-7542.	1.6	2
207	Efficacy and safety results from CurrentS, a double-blind, randomized, phase III study of second-line erlotinib (150 mg versus 300 mg) in current smokers with advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2014, 32, 8046-8046.	1.6	2
208	Treatment decision-making for advanced non-small cell lung cancer and differences among European countries: 1st AIOT-ETOP meeting. Lung Cancer, 2011, 74, 544-548.	2.0	1
209	Osimertinib-related skin and mucosal adverse events. Cancer Treatment and Research Communications, 2017, 12, 53-55.	1.7	1
210	Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials. European Journal of Cancer, 2021, 155, 168-178.	2.8	1
211	Never-smoking women with lung cancer from the Spanish WORLD07 database.. Journal of Clinical Oncology, 2012, 30, 1531-1531.	1.6	1
212	Population survey to assess the knowledge of smoking habit and its consequences on women (w) in Spain.. Journal of Clinical Oncology, 2012, 30, e12000-e12000.	1.6	1
213	Afatinib in combination with pembrolizumab in patients (pts) with stage IIIB/IV squamous cell carcinoma (SCC) of the lung.. Journal of Clinical Oncology, 2018, 36, TPS9117-TPS9117.	1.6	1
214	Brain metastases: the need for a more tailored approach in non-small-cell lung cancer patients. Clinical and Translational Oncology, 2012, 14, 1-2.	2.4	0
215	El c�ncer de pulm�n en mujeres. Arbor, 2015, 191, a235.	0.3	0
216	SAMHD1 Is a Modulator of Nucleos(t)ide Analogues�™ Efficacy. Proceedings (mdpi), 2020, 50, 58.	0.2	0

#	ARTICLE	IF	CITATIONS
217	GAIN-(L): Efficacy and biomarker findings of RG7160 (GA201), a novel, dual-acting monoclonal antibody (mAb) designed to enhance antibody-dependent cellular cytotoxicity (ADCC), in combination with first-line cisplatin and pemetrexed in metastatic nonsquamous NSCLC.. Journal of Clinical Oncology, 2012, 30, 7544-7544.	1.6	0
218	Amplification of fibroblast growth factor receptor type 1 gene (FGFR1) in samples from 101 NSCLC patients (pts) with squamous cell carcinoma (SCC) histology.. Journal of Clinical Oncology, 2012, 30, 7041-7041.	1.6	0
219	Adjuvant Chemotherapy: Feasibility in the Elderly and Patient Selection. , 2013, , 165-172.		0
220	Is There a Role for Neoadjuvant Chemotherapy in Older Patients?. , 2013, , 141-150.		0
221	ROR1 mRNA expression in EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p) with the T790M mutation: A potential therapeutic target.. Journal of Clinical Oncology, 2013, 31, 11027-11027.	1.6	0
222	Whole-exome sequencing in tumor samples from sequenom-wild-type, ALK negative stage IV lung adenocarcinoma (ADC) patients (p).. Journal of Clinical Oncology, 2013, 31, 8070-8070.	1.6	0
223	Effect of BIM and mTOR expression on clinical outcome to erlotinib in EGFR-mutant non-small cell lung cancer (NSCLC) patients (p).. Journal of Clinical Oncology, 2014, 32, 8072-8072.	1.6	0
224	Incorporation of FGFR1 and FGFR2 amplification status determination in routine molecular prescreening for targeted therapies.. Journal of Clinical Oncology, 2014, 32, 11105-11105.	1.6	0
225	The HALO study: A phase I-II of the oral HSP90 inhibitor Debio0932 in combination with SOC in first- and second-line therapy of advanced NSCLC.. Journal of Clinical Oncology, 2014, 32, TPS2632-TPS2632.	1.6	0
226	Analysis of expression of PTEN/PI3K pathway and programmed cell death 1 ligand 1 (PD-L1) in malignant pleural mesothelioma (MPM).. Journal of Clinical Oncology, 2015, 33, e18540-e18540.	1.6	0
227	Afatinib (A) vs erlotinib (E) as second-line treatment of patients (pts) with advanced squamous cell carcinoma (SCC) of the lung following first-line platinum-based chemotherapy: Patient-reported outcome (PRO) data from the LUX-Lung 8 Phase III global trial.. Journal of Clinical Oncology, 2015, 33, 8100-8100.	1.6	0
228	Rociletinib-related bilateral cataract. Precision Cancer Medicine, 0, 1, 3-3.	1.8	0
229	Clinical utility of plasma-based digital next-generation sequencing (NGS) in patients with advance-stage lung adenocarcinomas with insufficient tumor samples for tissue genotyping.. Journal of Clinical Oncology, 2018, 36, 9101-9101.	1.6	0
230	MS201944-0170: A phase IIa study to investigate the clinical activity and safety of avelumab in combination with cetuximab plus gemcitabine and cisplatin in patients with advanced squamous NSCLC.. Journal of Clinical Oncology, 2019, 37, TPS9123-TPS9123.	1.6	0
231	Angiogenesis, multitarget kinase inhibitors and non-small cell lung cancer: a lesson from MONET1 trial. Translational Lung Cancer Research, 2013, 2, E13-6.	2.8	0
232	Chemotherapy in resectable non-small cell lung cancer. , 2004, 6, 52-56.		0